Skip to main content
NCBI home page
Protein Science : A Publication of the Protein Society logoLink to Protein Science : A Publication of the Protein Society
. 1993 May;2(5):786–799. doi: 10.1002/pro.5560020509

Binding of amino acid side chains to preformed cavities: interaction of serine proteinases with turkey ovomucoid third domains with coded and noncoded P1 residues.

T L Bigler 1, W Lu 1, S J Park 1, M Tashiro 1, M Wieczorek 1, R Wynn 1, M Laskowski Jr 1
PMCID: PMC2142496  PMID: 8495199

Abstract

In the association of serine proteinases with their cognate substrates and inhibitors an important interaction is the fitting of the P1 side chain of the substrate or inhibitor into a preformed cavity of the enzyme called the S1 pocket. In turkey ovomucoid third domain, which is a canonical protein proteinase inhibitor, the P1 residue is Leu18. Here we report the values of equilibrium constants, Ka, for turkey ovomucoid third domain and 13 additional Leu18X variants with six serine proteinases: bovine alpha chymotrypsin A, porcine pancreatic elastase, subtilisin Carlsberg, Streptomyces griseus proteinases A and B, and human leukocyte elastase. Eight of the Xs are coded amino acids: Ala, Ser, Val, Met, Gln, Glu, Lys, and Phe, and five are noncoded: Abu, Ape, Ahx, Ahp, and Hse. They were chosen to simplify the interamino acid comparisons. In the homologous series of straight-chain side chains Ala, Abu, Ape, Ahx, Ahp, free energy of binding decreases monotonically with the side-chain length for chymotrypsin with large binding pocket, but even for this enzyme shows curvature. For the two S. griseus enzymes a minimum appears to be reached at Ahp. A minimum is clearly evident for the two elastases, where increasing the side-chain length from Ahx to Ahp greatly weakens binding, but much more so for the apparently more rigid pancreatic enzyme than for the more flexible leukocyte enzyme. beta-Branching (Ape/Val) is very deleterious for five of the six enzymes; it is only slightly deleterious for the more flexible human leukocyte elastase. The effect of gamma-branching (Ahx/Leu), of introduction of heteroatoms (Abu/Ser), (Ape/Hse), and (Ahx/Met), and of introduction of charge (Gln/Glu) and (Ahp/Lys) are tabulated and discussed. An important component of the free energy of interaction is the distortion of the binding pocket by bulky or branched side chains. Most of the variants studied were obtained by enzymatic semisynthesis. X18 variants of the 6-18 peptide GlyNH2 were synthesized and combined with natural reduced peptide 19-56. Disulfide bridges were formed. The GlyNH2 was removed and the reactive-site peptide bond X18-Glu19 was synthesized by complex formation with proteinase K. The resultant complexes were dissociated by sudden pH drop. This kinetically controlled dissociation afforded virgin, reactive-site-intact inhibitor variants.

Full Text

The Full Text of this article is available as a PDF (1.3 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anfinsen C. B., Corley L. G. An active variant of staphylococcal nuclease containing norleucine in place of methionine. J Biol Chem. 1969 Oct 10;244(19):5149–5152. [PubMed] [Google Scholar]
  2. Ardelt W., Laskowski M., Jr Effect of single amino acid replacements on the thermodynamics of the reactive site peptide bond hydrolysis in ovomucoid third domain. J Mol Biol. 1991 Aug 20;220(4):1041–1053. doi: 10.1016/0022-2836(91)90370-l. [DOI] [PubMed] [Google Scholar]
  3. Ardelt W., Laskowski M., Jr Thermodynamics and kinetics of the hydrolysis and resynthesis of the reactive site peptide bond in turkey ovomucoid third domain by aspergillopeptidase B. Acta Biochim Pol. 1983;30(2):115–126. [PubMed] [Google Scholar]
  4. Beckmann J., Mehlich A., Schröder W., Wenzel H. R., Tschesche H. Preparation of chemically 'mutated' aprotinin homologues by semisynthesis. P1 substitutions change inhibitory specificity. Eur J Biochem. 1988 Oct 1;176(3):675–682. doi: 10.1111/j.1432-1033.1988.tb14330.x. [DOI] [PubMed] [Google Scholar]
  5. Benjamin D. C., Berzofsky J. A., East I. J., Gurd F. R., Hannum C., Leach S. J., Margoliash E., Michael J. G., Miller A., Prager E. M. The antigenic structure of proteins: a reappraisal. Annu Rev Immunol. 1984;2:67–101. doi: 10.1146/annurev.iy.02.040184.000435. [DOI] [PubMed] [Google Scholar]
  6. Bode W., Epp O., Huber R., Laskowski M., Jr, Ardelt W. The crystal and molecular structure of the third domain of silver pheasant ovomucoid (OMSVP3). Eur J Biochem. 1985 Mar 1;147(2):387–395. doi: 10.1111/j.1432-1033.1985.tb08762.x. [DOI] [PubMed] [Google Scholar]
  7. Bode W., Huber R. Natural protein proteinase inhibitors and their interaction with proteinases. Eur J Biochem. 1992 Mar 1;204(2):433–451. doi: 10.1111/j.1432-1033.1992.tb16654.x. [DOI] [PubMed] [Google Scholar]
  8. Bode W., Wei A. Z., Huber R., Meyer E., Travis J., Neumann S. X-ray crystal structure of the complex of human leukocyte elastase (PMN elastase) and the third domain of the turkey ovomucoid inhibitor. EMBO J. 1986 Oct;5(10):2453–2458. doi: 10.1002/j.1460-2075.1986.tb04521.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Creighton T. E., Darby N. J. Functional evolutionary divergence of proteolytic enzymes and their inhibitors. Trends Biochem Sci. 1989 Aug;14(8):319–324. doi: 10.1016/0968-0004(89)90159-x. [DOI] [PubMed] [Google Scholar]
  10. Cunningham B. C., Wells J. A. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science. 1989 Jun 2;244(4908):1081–1085. doi: 10.1126/science.2471267. [DOI] [PubMed] [Google Scholar]
  11. Davies D. R., Sheriff S., Padlan E. A. Antibody-antigen complexes. J Biol Chem. 1988 Aug 5;263(22):10541–10544. [PubMed] [Google Scholar]
  12. Dill K. A. Dominant forces in protein folding. Biochemistry. 1990 Aug 7;29(31):7133–7155. doi: 10.1021/bi00483a001. [DOI] [PubMed] [Google Scholar]
  13. Dorovska V. N., Varfolomeyev S. D., Kazanskaya N. F., Klyosov A. A., Martinek K. The influence of the geometric properties of the active centre on the specificity of -chymotrypsin catalysis. FEBS Lett. 1972 Jun 1;23(1):122–124. doi: 10.1016/0014-5793(72)80299-0. [DOI] [PubMed] [Google Scholar]
  14. Empie M. W., Laskowski M., Jr Thermodynamics and kinetics of single residue replacements in avian ovomucoid third domains: effect on inhibitor interactions with serine proteinases. Biochemistry. 1982 May 11;21(10):2274–2284. doi: 10.1021/bi00539a002. [DOI] [PubMed] [Google Scholar]
  15. Eriksson A. E., Baase W. A., Zhang X. J., Heinz D. W., Blaber M., Baldwin E. P., Matthews B. W. Response of a protein structure to cavity-creating mutations and its relation to the hydrophobic effect. Science. 1992 Jan 10;255(5041):178–183. doi: 10.1126/science.1553543. [DOI] [PubMed] [Google Scholar]
  16. Estell D. A., Graycar T. P., Miller J. V., Powers D. B., Wells J. A., Burnier J. P., Ng P. G. Probing steric and hydrophobic effects on enzyme-substrate interactions by protein engineering. Science. 1986 Aug 8;233(4764):659–663. doi: 10.1126/science.233.4764.659. [DOI] [PubMed] [Google Scholar]
  17. Finkenstadt W. R., Laskowski M., Jr Resynthesis by trypsin of the cleaved peptide bond in modified soybean trypsin inhibitor. J Biol Chem. 1967 Feb 25;242(4):771–773. [PubMed] [Google Scholar]
  18. Fujinaga M., Read R. J., Sielecki A., Ardelt W., Laskowski M., Jr, James M. N. Refined crystal structure of the molecular complex of Streptomyces griseus protease B, a serine protease, with the third domain of the ovomucoid inhibitor from turkey. Proc Natl Acad Sci U S A. 1982 Aug;79(16):4868–4872. doi: 10.1073/pnas.79.16.4868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Fujinaga M., Sielecki A. R., Read R. J., Ardelt W., Laskowski M., Jr, James M. N. Crystal and molecular structures of the complex of alpha-chymotrypsin with its inhibitor turkey ovomucoid third domain at 1.8 A resolution. J Mol Biol. 1987 May 20;195(2):397–418. doi: 10.1016/0022-2836(87)90659-0. [DOI] [PubMed] [Google Scholar]
  20. Harper J. W., Cook R. R., Roberts C. J., McLaughlin B. J., Powers J. C. Active site mapping of the serine proteases human leukocyte elastase, cathepsin G, porcine pancreatic elastase, rat mast cell proteases I and II. Bovine chymotrypsin A alpha, and Staphylococcus aureus protease V-8 using tripeptide thiobenzyl ester substrates. Biochemistry. 1984 Jun 19;23(13):2995–3002. doi: 10.1021/bi00308a023. [DOI] [PubMed] [Google Scholar]
  21. Horovitz A., Serrano L., Fersht A. R. COSMIC analysis of the major alpha-helix of barnase during folding. J Mol Biol. 1991 May 5;219(1):5–9. doi: 10.1016/0022-2836(91)90852-w. [DOI] [PubMed] [Google Scholar]
  22. Kojima S., Nishiyama Y., Kumagai I., Miura K. Inhibition of subtilisin BPN' by reaction site P1 mutants of Streptomyces subtilisin inhibitor. J Biochem. 1991 Mar;109(3):377–382. doi: 10.1093/oxfordjournals.jbchem.a123389. [DOI] [PubMed] [Google Scholar]
  23. Komiyama T., Bigler T. L., Yoshida N., Noda K., Laskowski M., Jr Replacement of P1 Leu18 by Glu18 in the reactive site of turkey ovomucoid third domain converts it into a strong inhibitor of Glu-specific Streptomyces griseus proteinase (GluSGP). J Biol Chem. 1991 Jun 15;266(17):10727–10730. [PubMed] [Google Scholar]
  24. Laskowski M., Jr An algorithmic approach to sequence leads to reactivity of proteins. Specificity of protein inhibitors of serine proteinases. Biochem Pharmacol. 1980 Aug 1;29(15):2089–2094. doi: 10.1016/0006-2952(80)90177-x. [DOI] [PubMed] [Google Scholar]
  25. Laskowski M., Jr, Kato I., Ardelt W., Cook J., Denton A., Empie M. W., Kohr W. J., Park S. J., Parks K., Schatzley B. L. Ovomucoid third domains from 100 avian species: isolation, sequences, and hypervariability of enzyme-inhibitor contact residues. Biochemistry. 1987 Jan 13;26(1):202–221. doi: 10.1021/bi00375a028. [DOI] [PubMed] [Google Scholar]
  26. Laskowski M., Jr, Kato I., Kohr W. J., Park S. J., Tashiro M., Whatley H. E. Positive darwinian selection in evolution of protein inhibitors of serine proteinases. Cold Spring Harb Symp Quant Biol. 1987;52:545–553. doi: 10.1101/sqb.1987.052.01.062. [DOI] [PubMed] [Google Scholar]
  27. Laskowski M., Jr, Kato I. Protein inhibitors of proteinases. Annu Rev Biochem. 1980;49:593–626. doi: 10.1146/annurev.bi.49.070180.003113. [DOI] [PubMed] [Google Scholar]
  28. Laskowski M., Jr Protein inhibitors of serine proteinases--mechanism and classification. Adv Exp Med Biol. 1986;199:1–17. doi: 10.1007/978-1-4757-0022-0_1. [DOI] [PubMed] [Google Scholar]
  29. Mendel D., Ellman J. A., Chang Z., Veenstra D. L., Kollman P. A., Schultz P. G. Probing protein stability with unnatural amino acids. Science. 1992 Jun 26;256(5065):1798–1802. doi: 10.1126/science.1615324. [DOI] [PubMed] [Google Scholar]
  30. Nozaki Y., Tanford C. The solubility of amino acids and two glycine peptides in aqueous ethanol and dioxane solutions. Establishment of a hydrophobicity scale. J Biol Chem. 1971 Apr 10;246(7):2211–2217. [PubMed] [Google Scholar]
  31. Read R. J., Fujinaga M., Sielecki A. R., James M. N. Structure of the complex of Streptomyces griseus protease B and the third domain of the turkey ovomucoid inhibitor at 1.8-A resolution. Biochemistry. 1983 Sep 13;22(19):4420–4433. doi: 10.1021/bi00288a012. [DOI] [PubMed] [Google Scholar]
  32. Schechter I., Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun. 1967 Apr 20;27(2):157–162. doi: 10.1016/s0006-291x(67)80055-x. [DOI] [PubMed] [Google Scholar]
  33. Sealock R. W., Laskowski M., Jr Enzymatic replacement of the arginyl by a lysyl residue in the reactive site of soybean trypsin inhibitor. Biochemistry. 1969 Sep;8(9):3703–3710. doi: 10.1021/bi00837a032. [DOI] [PubMed] [Google Scholar]
  34. Sharp K. A., Nicholls A., Friedman R., Honig B. Extracting hydrophobic free energies from experimental data: relationship to protein folding and theoretical models. Biochemistry. 1991 Oct 8;30(40):9686–9697. doi: 10.1021/bi00104a017. [DOI] [PubMed] [Google Scholar]
  35. Tschesche H., Beckmann J., Mehlich A., Schnabel E., Truscheit E., Wenzel H. R. Semisynthetic engineering of proteinase inhibitor homologues. Biochim Biophys Acta. 1987 May 27;913(1):97–101. doi: 10.1016/0167-4838(87)90238-x. [DOI] [PubMed] [Google Scholar]
  36. Weber E., Papamokos E., Bode W., Huber R., Kato I., Laskowski M., Jr Crystallization, crystal structure analysis and molecular model of the third domain of Japanese quail ovomucoid, a Kazal type inhibitor. J Mol Biol. 1981 Jun 15;149(1):109–123. doi: 10.1016/0022-2836(81)90263-1. [DOI] [PubMed] [Google Scholar]
  37. Wells J. A. Additivity of mutational effects in proteins. Biochemistry. 1990 Sep 18;29(37):8509–8517. doi: 10.1021/bi00489a001. [DOI] [PubMed] [Google Scholar]
  38. Wieczorek M., Laskowski M., Jr Formation of covalent hybrids from amino-terminal and carboxy-terminal fragments of two ovomucoid third domains. Biochemistry. 1983 May 24;22(11):2630–2636. doi: 10.1021/bi00280a006. [DOI] [PubMed] [Google Scholar]
  39. Wieczorek M., Park S. J., Laskowski M., Jr Covalent hybrids of ovomucoid third domains made from one synthetic and one natural peptide chain. Biochem Biophys Res Commun. 1987 Apr 14;144(1):499–504. doi: 10.1016/s0006-291x(87)80537-5. [DOI] [PubMed] [Google Scholar]

Articles from Protein Science : A Publication of the Protein Society are provided here courtesy of The Protein Society

RESOURCES